GlassScriptPhysician profile
Jodi Dixon
NPI 1801372313
$4,080.26
in general payments reported to CMS, 2019-2025
23 companies · $1,298 in 2025
The $1,298 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2022: $400 · 2023: $771 · 2024: $1,398 · 2025: $1,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,466.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,333.82 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $517.44 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $439.86 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.77 | 2022-2025 | Ofev |
| Jazz Pharmaceuticals INC. | $271.62 | 2021-2025 | |
| Genzyme Corporation | $255.47 | 2024-2025 | |
| Grifols USA, LLC | $179.78 | 2021-2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $178.40 | 2021-2024 | Yupelri |
| Inspire Medical Systems, INC. | $115.83 | 2023-2025 | Inspire |
| Intuitive Surgical, INC. | $77.29 | 2025 | |
| Merck Sharp & Dohme LLC | $68.62 | 2023-2025 | Zerbaxa, Recarbrio, Dificid |
| Axsome Therapeutics, INC. | $59.26 | 2023-2025 | Sunosi |
| Verona Pharma, INC. | $55.33 | 2025 | Ohtuvayre |
| Baxter Healthcare | $42.06 | 2024 | Hillrom - Monarch Airway Clearance System |
| Amgen INC. | $26.19 | 2024 | Tezspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $25.85 | 2023 | Fisher & Paykel Healthcare |
| United Therapeutics Corporation | $25.09 | 2024 | Tyvaso |
| Viatris Specialty LLC | $24.67 | 2025 | Yupelri |
| Pfizer INC. | $23.84 | 2023 | |
| Abbvie INC. | $23.72 | 2023 | |
| Alexion Pharmaceuticals, INC. | $21.68 | 2023 | Soliris |
| Paratek Pharmaceuticals, INC. | $17.40 | 2022 | |
| 3b Medical, INC. | $14.27 | 2024 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.